{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:09:12Z","timestamp":1790201352947,"version":"4.1.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Detecting autoantibodies provides foundational information for the diagnosis of most autoimmune diseases. An important pathophysiological distinction is whether autoantibodies are directed against extracellular or intracellular proteins. Autoantibodies targeting extracellular domains of proteins, such as membrane receptors, channels or secreted molecules are often directly pathogenic, whereby autoantibody binding to the autoantigen disrupts the normal function of a critical protein or pathway, and\/or triggers antibody-dependent cell surface complement killing. By comparison, autoantibodies directed against intracellular proteins are recognized as useful diagnostic biomarkers of abnormal autoimmune activity, but the link between antigenicity and pathogenicity is less straightforward. Because intracellular autoantigens are generally inaccessible to autoantibody binding, for the most part, they do not directly contribute to pathogenesis. In a few diseases, autoantibodies to intracellular targets cause damage indirectly by immune complex formation, immune activation, and other processes. In this review, the general features of and differences between autoimmune diseases segregated on the basis of intracellular or extracellular autoantigens are explored using over twenty examples. Expression profiles of autoantigens in relation to the tissues targeted by autoimmune disease and the temporal appearance of autoantibodies before clinical diagnosis often correlate with whether the respective autoantibodies mostly recognize either intracellular or extracellular autoantigens. In addition, current therapeutic strategies are discussed from this vantage point. One drug, rituximab, depletes CD20+ B-cells and is highly effective for autoimmune disorders associated with autoantibodies against extracellular autoantigens. In contrast, diseases associated with autoantibodies directed predominately against intracellular autoantigens show much more complex immune cell involvement, such as T-cell mediated tissue damage, and require different strategies for optimal therapeutic benefit. Understanding the clinical ramifications of autoimmunity derived by autoantibodies against either intracellular or extracellular autoantigens, or a spectrum of both, has practical implications for guiding drug development, generating monitoring tools, stratification of patient interventions, and designing trials based on predictive autoantibody profiles for autoimmune diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2021.548469","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:57:26Z","timestamp":1615165046000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":91,"title":["Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity"],"prefix":"10.3389","volume":"12","author":[{"given":"Peter D.","family":"Burbelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Iadarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake M.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key064","article-title":"Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus","volume":"58","author":"Carreira","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-016-0211-6","article-title":"Transcriptomic Segregation of Human Autoantigens Useful for the Diagnosis of Autoimmune Diseases","volume":"20","author":"Burbelo","year":"2016","journal-title":"Mol Diagn Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00050-16","article-title":"Coordinated Neutralization and Immune Activation by the Cytosolic Antibody Receptor TRIM21","volume":"90","author":"Fletcher","year":"2016","journal-title":"J Virol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1038\/s41598-018-21522-7","article-title":"Autoantibodies against the Immunoglobulin-Binding Region of Ro52 Link its Autoantigenicity with Pathogen Neutralization","volume":"8","author":"Burbelo","year":"2018","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0065-2776(08)60298-9","article-title":"Immune complex disease in experimental animals and man","volume":"16","author":"Cochrane","year":"1973","journal-title":"Adv Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0895","article-title":"Nature and functions of autoantibodies","volume":"4","author":"Elkon","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e32001","DOI":"10.1371\/journal.pone.0032001","article-title":"Two major autoantibody clusters in systemic lupus erythematosus","volume":"7","author":"Ching","year":"2012","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013417","article-title":"Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus","volume":"63","author":"Hoffman","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23587","article-title":"Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(90)90057-M","article-title":"Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus","volume":"20","author":"ter Borg","year":"1990","journal-title":"Semin Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.39316","article-title":"Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0254-y","article-title":"The heterogeneous pathogenesis of type 1 diabetes mellitus","volume":"15","author":"Ilonen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11892-016-0738-2","article-title":"Islet Autoantibodies","volume":"16","author":"Lampasona","year":"2016","journal-title":"Curr Diabetes Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/mus.25565","article-title":"GAD65 neurological autoimmunity","volume":"56","author":"McKeon","year":"2017","journal-title":"Muscle Nerve"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1058","article-title":"Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes","volume":"65","author":"McLaughlin","year":"2016","journal-title":"Diabetes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1021\/acs.jproteome.6b00354","article-title":"Tracking the Antibody Immunome in Type 1 Diabetes Using Protein Arrays","volume":"16","author":"Bian","year":"2017","journal-title":"J\u00a0Proteome Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.clim.2018.07.001","article-title":"Novel minor HLA DR associated antigens in type 1 diabetes","volume":"194","author":"Muller","year":"2018","journal-title":"Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb06518.x","article-title":"Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo","volume":"95","author":"Csernok","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.11.4115","article-title":"Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro","volume":"87","author":"Falk","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.153.3.1271","article-title":"Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa","volume":"153","author":"Porges","year":"1994","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of Autoantibody-Induced Pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2174\/157015911796557966","article-title":"Autoimmune channelopathies of the nervous system","volume":"9","author":"Kleopa","year":"2011","journal-title":"Curr Neuropharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-Mediated Encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.11.006","article-title":"Goodpasture\u2019s syndrome: a clinical update","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11761116","article-title":"Primary Membranous Nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120222","article-title":"Anticytokine autoantibody-associated immunodeficiency","volume":"32","author":"Browne","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023226","article-title":"Pulmonary alveolar proteinosis","volume":"349","author":"Trapnell","year":"2003","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202526","article-title":"Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis","volume":"190","author":"Rosen","year":"2013","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu968","article-title":"Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated\/extrapulmonary nocardiosis","volume":"60","author":"Rosen","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111160","article-title":"Adult-onset immunodeficiency in Thailand and Taiwan","volume":"367","author":"Browne","year":"2012","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70201-7","article-title":"Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment","volume":"14","author":"Engel","year":"2015","journal-title":"Lancet Neurol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0329-y","article-title":"Complexities of the glomerular basement membrane","author":"Naylor","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.08.010","article-title":"Familial chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1","volume":"8","author":"Ahmad","year":"2014","journal-title":"J Clin Lipidol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611930","article-title":"Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia","volume":"376","author":"Beigneux","year":"2017","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.coph.2014.11.008","article-title":"NMDA receptor subunit mutations in neurodevelopmental disorders","volume":"20","author":"Burnashev","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi034","article-title":"An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia","volume":"14","author":"Benet-Pages","year":"2005","journal-title":"Hum Mol Genet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122004","article-title":"Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies","volume":"128","author":"Roberts","year":"2018","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0101","article-title":"Predicting type 1 diabetes using biomarkers","volume":"38","author":"Bonifacio","year":"2015","journal-title":"Diabetes Care"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.09.008","article-title":"Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity","volume":"26","author":"Bustamante","year":"2014","journal-title":"Semin Immunol"},{"key":"B53","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2933","article-title":"Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling","volume":"46","author":"Rice","year":"2014","journal-title":"Nat Genet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278448","article-title":"Autoantibodies present before symptom onset in primary Sjogren syndrome","volume":"310","author":"Jonsson","year":"2013","journal-title":"JAMA"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e0214202","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PLoS One"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010090928","article-title":"Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease","volume":"22","author":"Olson","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019050538","article-title":"Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy","volume":"31","author":"Burbelo","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0228","article-title":"Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease","volume":"96","author":"Hutfless","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.bloodjournal832435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.04.003","article-title":"Rituximab in anti-GBM disease: A retrospective study of 8 patients","volume":"60","author":"Touzot","year":"2015","journal-title":"J Autoimmun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1508234","article-title":"Long-Term Remissions in Recalcitrant Pemphigus Vulgaris","volume":"373","author":"Ahmed","year":"2015","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395707","article-title":"Anti-CD20 (rituximab) therapy for anti-IFN-gamma autoantibody-associated nontuberculous mycobacterial infection","volume":"119","author":"Browne","year":"2012","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2018.17096","article-title":"Outcomes of rituximab therapy in refractory lupus: A meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.151","article-title":"Anti-DNA antibodies\u2013quintessential biomarkers of SLE","volume":"12","author":"Pisetsky","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B69","article-title":"B cell depletion with rituximab in the treatment of primary Sjogren\u2019s syndrome: what have we learnt","author":"Grigoriadou","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren\u2019s Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B74","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1902226","article-title":"An Anti-CD3 Antibody, Teplizumab","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B76","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10067-016-3436-1","article-title":"Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group","volume":"36","author":"Fleischmann","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/ard.47.9.768","article-title":"Tumour necrosis factor in synovial exudates","volume":"47","author":"Di Giovine","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/BF00920793","article-title":"Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4\/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures","volume":"12","author":"Beckham","year":"1992","journal-title":"J Clin Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-alpha agents - Comparison among therapeutic TNF-alpha antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1191\/096120300674499064","article-title":"Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheumatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/art.11311","article-title":"Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren\u2019s syndrome","volume":"48","author":"Salomonsson","year":"2003","journal-title":"Arthritis Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2012.07.003","article-title":"Secreted human Ro52 autoantibody proteomes express a restricted set of public clonotypes","volume":"39","author":"Arentz","year":"2012","journal-title":"J Autoimmun"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.01.029","article-title":"Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody","author":"Singh","year":"2020","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B93","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jacl.2014.08.010","article-title":"Familial chylomicronemia syndrome and response to medium-chaintriglyceride therapy in an infant with novel mutations in GPIHBP1","volume":"8","author":"Ahmad","year":"2014","journal-title":"J ClinLipidol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.coph.2014.11.008","article-title":"NMDA receptor subunit mutations in neurodevelopmentaldisorders","volume":"20","author":"Burnashev","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi034","article-title":"An FGF23 missense mutation causes familial tumoral calcinosis withhyperphosphatemia","volume":"14","author":"Benet-Pages","year":"2016","journal-title":"Hum Mol Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.548469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T13:26:47Z","timestamp":1697981207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.548469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":96,"alternative-id":["10.3389\/fimmu.2021.548469"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.548469","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"article-number":"548469"}}